Status:
COMPLETED
Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients
Lead Sponsor:
University of Alberta
Conditions:
Transplant
Eligibility:
All Genders
18-75 years
Brief Summary
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant...
Detailed Description
OBJECTIVE AND HYPOTHESIS * To test the specific humoral response of the influenza vaccine after islet cell transplantation * To test the production of HLA alloantibodies after vaccination.
Eligibility Criteria
Inclusion
- Adult islet cell transplant recipients
- Able to provide informed consent
Exclusion
- Egg allergy
- Previous life-threatening reaction to influenza vaccine (ie Guillain Barre Syndrome)
- Febrile illness in the past two weeks
- Unable to provide informed consent
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT01149382
Start Date
August 1 2010
End Date
December 1 2011
Last Update
August 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2E1